Systematic review and meta-analysis concerning the efficacy and effectiveness of seasonal influenza vaccines – (part 1)Archived
This is an authoritative independent evidence-based review and meta-analysis of the efficacy and effectiveness of influenza vaccines. It confines itself to trials and observational studies where diagnostic tests confirmed influenza infection as the end point.
Systematic review and meta-analysis concerning the efficacy and effectiveness of seasonal influenza vaccines – (part 2)Archived
Systematic review and meta-analysis concerning the efficacy and effectiveness of seasonal influenza vaccines
The importance of analyses of antigenic match and monitoring influenza vaccine effectivenessArchived
Influenza viruses pose a particular challenge for those designing vaccines for humans. Much of the protective immunity that humans have against these viruses following natural infection or vaccination is due to immunological recognition of the haemagglutinin (HA) surface glycoprotein.
Lower than usual: early influenza vaccine effectiveness in parts of Europe in season 2011/12Archived
A rapid communication published on April 12th 2012 describes the early results of the annual multicentre case-control study undertaken by the ECDC sponsored I-MOVE consortium whose work is coordinated by an Epiconcept team
WHO issues recommendation on the composition of influenza virus vaccines for the northern hemisphere 2015-2016
The World Health Organization (WHO) has agreed on the recommended composition of the trivalent influenza vaccine for the northern hemisphere 2015-2016 influenza season.
Influenza vaccine effectiveness: results of the ECDC/I-MOVE studies and other studiesArchived
On the 26 October 2011, The Lancet Infectious Diseases published a systematic review and a meta-analysis, combining the results of several studies undertaken on influenza vaccine effectiveness.
Low uptake of seasonal influenza vaccination in Europe may jeopardise capacity to protect people in next pandemic
Influenza vaccination coverage among high-risk groups has dropped in the European Region over the last seven years, and half the countries report a decrease in the number of vaccine doses available.